New York, NY – NEXGEL, Inc. held its quarterly earnings conference call on April 1, 2024, led by company executives discussing the financial results and growth outlook for the future. Key figures present during the call included Valter Pinto, Managing Director of KCSA Strategic Communications; Adam Levy, the Chief Executive Officer; and Adam Drapczuk, the Chief Financial Officer. The latest earnings report highlighted NEXGEL’s remarkable performance in 2023 and the strategic initiatives taken to position the company for significant growth moving forward.

During the call, Adam Levy emphasized the company’s achievements in 2023, noting a nearly 100% increase in revenue to $4.1 million. This growth was attributed to expansions in contract manufacturing and branded products. While revenue saw a slight sequential decrease in the fourth quarter due to seasonal trends, the overall trend indicated a positive trajectory for future growth. Specifically, the branded products revenue showed significant year-over-year and sequential increases, demonstrating strong consumer demand for products like Silverseal, a hospital-grade hydrogel dressing.

One of the highlights of the call was the discussion around NEXGEL’s plans to enter the European market by achieving MDR compliance. The company’s efforts in this area were highlighted, with expectations set for MDR compliance by mid-2024. The completion of this process would enable NEXGEL to tap into the European market for its Class I medical devices, opening up new growth opportunities.

Furthermore, the call addressed the company’s focus on improving gross profit margins through various strategies. NEXGEL highlighted its stable profit margins in branded products and the potential for increased margins in converting and packaging operations with the introduction of new automation equipment. Additionally, the partnership with AbbVie and the exclusive supply agreement for gel pads showcased a significant growth driver for NEXGEL, reinforcing the company’s innovative hydrogel technology.

As the call wrapped up, Adam Drapczuk, the CFO, provided a comprehensive review of the financial highlights for the fourth quarter and full year of 2023. The discussion touched upon key figures such as revenue growth, gross profit margins, and operational expenses, offering insight into the company’s financial performance and strategic investments.

Overall, the conference call underscored NEXGEL’s commitment to sustained growth, market expansion, and technological innovation in the medical and consumer health sectors. The company’s strategic partnerships, focus on compliance, and product diversification efforts position NEXGEL for continued success in the competitive market landscape.